Associated Papers
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
Saleh MN et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
Select a paper to view details